Women in India face a number of health challenges, including risks of miscarriages, infertility and other post-menopause related complications. Approximately one in five pregnancies in Indian women end in miscarriage. In addition, women who are in post-menopause may experience various short-, medium- and long- term complications, such as urogenital atrophy or osteoporosis.
Mylan aims to tackle these health issues through its Women’s Care segment, which focuses on treatments such as hormone replacement therapy, pre- and post-natal supplementation, post-menopause care and in-vitro fertilization treatments, such as follicle-stimulating hormones, human menopausal gonadotropins and human chorionic gonadotropins.
In addition to launching our innovative, high quality product portfolio, Mylan helps strengthen the capabilities of healthcare providers in this area through training programs and workshops, working together with the medical community and non-government organizations to address areas of concern in women's health and improve timely access to appropriate high quality treatment.